HeartSciences Inc.
$2.75
The Read: HeartSciences’ stock surged over 100% after MyoVista Insights gained Epic Toolbox Designation but then fell about 45% amid absent FDA feedback on its wavECG device and investor worries over cash burn despite initial SaaS revenue.
Price
Overlays
Panel
HSCS
Hover to view data
No Data